

# Juan-Manuel Sancho

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1037826/publications.pdf>

Version: 2024-02-01

148  
papers

2,122  
citations

304368

22  
h-index

276539

41  
g-index

167  
all docs

167  
docs citations

167  
times ranked

3132  
citing authors

#	ARTICLE	IF	CITATIONS
1	Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. <i>Lancet Haematology</i> , 2020, 7, e511-e522.	2.2	201
2	Identification of Leptomeningeal Disease in Aggressive B-Cell Non-Hodgkin's Lymphoma: Improved Sensitivity of Flow Cytometry. <i>Journal of Clinical Oncology</i> , 2009, 27, 1462-1469.	0.8	189
3	Evaluation of procalcitonin, neopterin, C-reactive protein, IL-6 and IL-8 as a diagnostic marker of infection in patients with febrile neutropenia. <i>Leukemia and Lymphoma</i> , 2008, 49, 1752-1761.	0.6	98
4	First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2014, 1, e104-e111.	2.2	77
5	Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma. <i>Cancer Medicine</i> , 2021, 10, 3214-3223.	1.3	73
6	Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial. <i>Lancet Haematology</i> , 2017, 4, e362-e373.	2.2	70
7	Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma. <i>Haematologica</i> , 2014, 99, 1228-1235.	1.7	69
8	Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. <i>European Journal of Haematology</i> , 2006, 78, 061114074547002-???	1.1	63
9	Central nervous system recurrence in adult patients with acute lymphoblastic leukemia. <i>Cancer</i> , 2006, 106, 2540-2546.	2.0	60
10	Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma. <i>Blood</i> , 2017, 130, 1772-1774.	0.6	60
11	Outcome and Prognostic Factors in Patients with Hematologic Malignancies Admitted to the Intensive Care Unit: A Single-Center Experience. <i>International Journal of Hematology</i> , 2007, 85, 195-202.	0.7	59
12	Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial. <i>Lancet Haematology</i> , 2018, 5, e543-e553.	2.2	53
13	Predictive factors for poor peripheral blood stem cell mobilization and peak CD34+ cell count to guide pre-emptive or immediate rescue mobilization. <i>Cytotherapy</i> , 2012, 14, 823-829.	0.3	50
14	Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era. <i>European Journal of Haematology</i> , 2010, 85, 321-328.	1.1	49
15	Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier. <i>Blood</i> , 2020, 135, 996-1007.	0.6	49
16	Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO). <i>Haematologica</i> , 2017, 102, 235-245.	1.7	40
17	HIV-infection impact on clinical biological features and outcome of diffuse large B-cell lymphoma treated with R-CHOP in the combination antiretroviral therapy era. <i>Aids</i> , 2015, 29, 811-818.	1.0	37
18	Efficacy and safety of liposomal cytarabine in lymphoma patients with central nervous system involvement from lymphoma. <i>Cancer</i> , 2009, 115, 1892-1898.	2.0	34

#	ARTICLE	IF	CITATIONS
19	Delayed haemolytic transfusion reaction due to anti-M antibody. <i>British Journal of Haematology</i> , 1998, 103, 268-269.	1.2	30
20	Contribution of cerebrospinal fluid sCD19 levels to the detection of CNS lymphoma and its impact on disease outcome. <i>Blood</i> , 2014, 123, 1864-1869.	0.6	30
21	<scp>MYC</scp> protein expression is associated with poor prognosis in primary diffuse large Bâ€cell lymphoma of the central nervous system. <i>Apmsis</i> , 2015, 123, 596-603.	0.9	29
22	Life expectancy of follicular lymphoma patients in complete response at 30Âmonths is similar to that of the Spanish general population. <i>British Journal of Haematology</i> , 2019, 185, 480-491.	1.2	26
23	Anti-CD47 Antibody, CC-90002, in Combination with Rituximab in Subjects with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL). <i>Blood</i> , 2019, 134, 4089-4089.	0.6	26
24	Usefulness and safety of oral cryotherapy in the prevention of oral mucositis after conditioning regimens with highâ€dose melphalan for autologous stem cell transplantation for lymphoma and myeloma. <i>European Journal of Haematology</i> , 2014, 93, 487-491.	1.1	23
25	Current prognostic and predictive factors in follicular lymphoma. <i>Annals of Hematology</i> , 2018, 97, 209-227.	0.8	22
26	Translocation (3;8)(q27;q24) in two cases of triple hit lymphoma. <i>Cancer Genetics and Cytogenetics</i> , 2010, 203, 328-332.	1.0	21
27	Refractoriness to immunochemotherapy in follicular lymphoma: Predictive factors and outcome. <i>Hematological Oncology</i> , 2017, 35, 520-527.	0.8	20
28	A Randomized Phase II Study Comparing Consolidation With a Single Dose Of 90y Ibritumomab Tiuxetan (ZevalinÂ®) (Z) Vs. Maintenance With Rituximab (R) For Two Years In Patients With Newly Diagnosed Follicular Lymphoma (FL) Responding To R-CHOP. Preliminary Results At 36 Months From Randomization. <i>Blood</i> , 2013, 122, 369-369.	0.6	20
29	The long term follow-up of early stage follicular lymphoma treated with radiotherapy, chemotherapy or combined modality treatment. <i>Leukemia Research</i> , 2015, 39, 853-858.	0.4	15
30	First European Chemotherapy Schedule for Elderly Patients with Acute Lymphoblastic Leukemia: Promising Remission Rate and Feasible Moderate Dose Intensity Consolidation. <i>Blood</i> , 2008, 112, 304-304.	0.6	15
31	Clinicopathologic features and prognostic significance of CD30 expression in <i>de novo</i> diffuse large B-cell lymphoma (DLBCL): results in a homogeneous series from a single institution. <i>Biomarkers</i> , 2020, 25, 69-75.	0.9	14
32	Mobilization and engraftment of peripheral blood stem cells in healthy related donors >55 years old. <i>Cytotherapy</i> , 2014, 16, 406-411.	0.3	13
33	Râ€COMP versus Râ€CHOP as firstâ€line therapy for diffuse large Bâ€cell lymphoma in patients â‰¥60Âyears: Results of a randomized phase 2 study from the Spanish GELTAMO group. <i>Cancer Medicine</i> , 2021, 10, 1314-1326.	1.3	13
34	Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
35	Results of Compassionate Therapy with Intrathecal Depot Liposomal Cytarabine in Acute Myeloid Leukemia Meningeosis. <i>International Journal of Hematology</i> , 2007, 86, 33-36.	0.7	12
36	Contempo: Preliminary Results in First-Line Treatment of Follicular Lymphoma with the Oral Dual PI3K-Î³ Inhibitor, Duvelisib, in Combination with Rituximab or Obinutuzumab. <i>Blood</i> , 2016, 128, 2979-2979.	0.6	12

#	ARTICLE	IF	CITATIONS
37	Prospective study on the practice of central nervous system prophylaxis and treatment in non-Hodgkin's lymphoma in Spain. <i>Medicina Clínica</i> , 2008, 131, 441-446.	0.3	11
38	Plasma Epstein-Barr Virus Load as an Early Biomarker and Prognostic Factor of Human Immunodeficiency Virus-related Lymphomas. <i>Clinical Infectious Diseases</i> , 2019, 68, 834-843.	2.9	11
39	Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study. <i>Journal of Hematology and Oncology</i> , 2021, 14, 111.	6.9	11
40	Pharmacokinetic and Safety of CT-P10, a Biosimilar Candidate to the Rituximab Reference Product, in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma (AFL). <i>Blood</i> , 2016, 128, 1807-1807.	0.6	11
41	Long-term follow-up of a prospective phase 2 clinical trial of extended treatment with rituximab in patients with B cell post-transplant lymphoproliferative disease and validation in real world patients. <i>Annals of Hematology</i> , 2021, 100, 1023-1029.	0.8	10
42	Long-Term Efficacy and Safety Results of CT-P10 and Reference Rituximab in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma: Phase III Updated Study Results with Median Follow-up of 40 Months. <i>Blood</i> , 2019, 134, 1528-1528.	0.6	10
43	Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Previously Treated with Ibrutinib (CITADEL-205). <i>Blood</i> , 2020, 136, 43-44.	0.6	10
44	CC-122 Expands Activated and Memory CD4 and CD8 T Cells In Vivo and Induces T Cell Activation Ex Vivo in Subjects with Relapsed or Refractory Diffuse Large B Cell Lymphoma and Multiple Myeloma. <i>Blood</i> , 2015, 126, 2704-2704.	0.6	10
45	Plerixafor plus G-CSF in combination with chemotherapy for stem cell mobilization in a pediatric patient with Ewing's sarcoma. <i>Journal of Clinical Apheresis</i> , 2012, 27, 260-262.	0.7	9
46	Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain. <i>Leukemia Research</i> , 2012, 36, 709-714.	0.4	9
47	Spanish Lymphoma Group (GELTAMO) guidelines for the diagnosis, staging, treatment, and follow-up of diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2018, 9, 32383-32399.	0.8	9
48	Incidence, predictive factors, management, and survival impact of atrial fibrillation in non-Hodgkin lymphoma. <i>Annals of Hematology</i> , 2018, 97, 1633-1640.	0.8	9
49	Recent landmark studies in follicular lymphoma. <i>Blood Reviews</i> , 2019, 35, 68-80.	2.8	9
50	Efficacy and safety of pixantrone for the treatment of multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas. <i>European Journal of Haematology</i> , 2020, 104, 499-508.	1.1	9
51	Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma. <i>Annals of Hematology</i> , 2020, 99, 2837-2846.	0.8	9
52	Final Results of a Multicenter Phase II Trial with Bendamustine and Rituximab As First Line Treatment for Patients with MALT Lymphoma (MALT-2008-01). <i>Blood</i> , 2012, 120, 3691-3691.	0.6	8
53	Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients. <i>Leukemia and Lymphoma</i> , 2022, 63, 538-550.	0.6	8
54	Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12 years follow-up of a phase 2 trial. <i>Annals of Hematology</i> , 2017, 96, 639-646.	0.8	7

#	ARTICLE	IF	CITATIONS
55	CC-122 Dosing on a Novel Intermittent Schedule Mitigates Neutropenia and Maintains Clinical Activity in Subjects with Relapsed or Refractory Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2015, 126, 1494-1494.	0.6	7
56	Targeting CD19 in diffuse large B-cell lymphoma: An expert opinion paper. <i>Hematological Oncology</i> , 2022, 40, 505-517.	0.8	7
57	Lymphomatoid Granulomatosis of Central Nervous System and Lung Driven by Epstein Barr Virus Proliferation: Successful Treatment with Rituximab. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2014, 6, e2014017.	0.5	6
58	Evaluation of Clinical and Biological Prognostic Factors in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients After Previous Treatment With Rituximab and Chemotherapy: Results of the PRO-R-IPI Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 398-403.	0.2	6
59	Treatment of localized stage follicular lymphoma. <i>European Journal of Haematology</i> , 2018, 101, 245-256.	1.1	6
60	Using the Lymph2Cx assay for assessing cell-of-origin subtypes of HIV-related diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 1087-1091.	0.6	6
61	Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma. <i>Future Oncology</i> , 2021, 17, 1295-1310.	1.1	6
62	Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 89-97.	0.2	6
63	Long-term efficacy and safety of CT-P10 or rituximab in untreated advanced follicular lymphoma: a randomized phase 3 study. <i>Blood Advances</i> , 2021, 5, 3354-3361.	2.5	6
64	Pembrolizumab for refractory primary mediastinal B-cell lymphoma with central nervous system involvement. <i>Hematological Oncology</i> , 2021, 39, 419-422.	0.8	6
65	Worse outcome and distinct mutational pattern in follicular lymphoma with anti-HBc positivity. <i>Blood Advances</i> , 2022, 6, 82-86.	2.5	6
66	Practice of central nervous system prophylaxis and treatment in acute leukemias in Spain. Prospective registry study. <i>Medicina Clínica</i> , 2008, 131, 401-405.	0.3	5
67	A new modified prophylactic scheme against liposomal cytarabine-induced arachnoiditis in adult patients with lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 892-893.	0.6	5
68	Flow cytometry for detection of central nervous system disease in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 2190-2192.	0.6	5
69	Relapse risk after autologous stem cell transplantation in patients with lymphoma based on CD34+ cell dose. <i>Leukemia and Lymphoma</i> , 2017, 58, 916-922.	0.6	5
70	Incidence of solid cancer in patients with follicular lymphoma. <i>Acta Oncológica</i> , 2019, 58, 1564-1569.	0.8	5
71	Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.2	5
72	A randomized phase II study comparing consolidation with a single dose of <sup>90</sup> Y ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results. <i>Leukemia and Lymphoma</i> , 2022, 63, 93-100.	0.6	5

#	ARTICLE	IF	CITATIONS
73	Title:Dose-Adjusted EPOCH Plus Rituximab (DA-EPOCH-R) in Untreated Patients with Poor Risk Large B-Cell Lymphoma. A Phase 2 Study Conducted by the Spanish PETHEMA Group.. Blood, 2009, 114, 2701-2701.	0.6	5
74	Epsteinâ€Barr viral loads and serum free light chains levels are potential follow-up markers of HIV-related lymphomas. Leukemia and Lymphoma, 2017, 58, 211-213.	0.6	4
75	Open questions in watchful waiting for follicular lymphoma. British Journal of Haematology, 2017, 179, 679-681.	1.2	4
76	Risk of Cardioembolic Stroke in Patients With Cancer and Atrial Fibrillation. American Journal of Cardiology, 2018, 121, 1656-1657.	0.7	4
77	Routine surveillance imaging in follicular lymphoma. Annals of Hematology, 2018, 97, 2263-2264.	0.8	4
78	Refractoriness to rituximab-based therapy and elevated serum B2-microglobulin predict for inferior survival in marginal zone lymphoma. Leukemia and Lymphoma, 2019, 60, 2524-2531.	0.6	4
79	Precision medicine in follicular lymphoma: Focus on predictive biomarkers. Hematological Oncology, 2020, 38, 625-639.	0.8	4
80	A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma. Investigational New Drugs, 2021, 39, 1028-1035.	1.2	4
81	Female patients with follicular lymphoma have a better prognosis if primary remission lasts over 24 months. Leukemia and Lymphoma, 2021, 62, 1639-1647.	0.6	4
82	Real-World Evidence of Tisagenlecleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma. Blood, 2020, 136, 19-21.	0.6	4
83	Global Phase I/III Pharmacokinetic and Efficacy Study Comparing CT-P10, a Biosimilar Candidate to the Rituximab Reference Product in Patients with Advanced Stage Follicular Lymphoma (AFL). Blood, 2015, 126, 5111-5111.	0.6	4
84	Revised International Prognostic Index and genetic alterations are associated with early failure to Râ€CHOP in patients with diffuse large Bâ€cell lymphoma. British Journal of Haematology, 2022, 196, 589-598.	1.2	4
85	Central nervous system relapse in diffuse large B cell lymphoma: Risk factors. Medicina ClÃnica (English Edition), 2016, 146, 74-80.	0.1	3
86	New drugs for follicular lymphoma. Leukemia Research, 2016, 49, 38-46.	0.4	3
87	Incidence and prognostic significance of nephrotoxicity in patients receiving eshap as salvage therapy for lymphoma. Leukemia Research, 2017, 58, 98-101.	0.4	3
88	La revisiÃ3n de 2016 de la clasificaciÃ3n de la OMS de las neoplasias linfoides: la visiÃ3n del clÃnico. Medicina ClÃnica, 2018, 150, 64-66.	0.3	3
89	Is there a role for the international prognostic index in follicular lymphoma?. Annals of Hematology, 2018, 97, 713-715.	0.8	3
90	Responseâ€adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after firstâ€line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial. Cancer Medicine, 2019, 8, 6955-6966.	1.3	3



#	ARTICLE	IF	CITATIONS
91	Evaluation of the MD Anderson tumor score for diffuse large B-cell lymphoma in the rituximab era. <i>European Journal of Haematology</i> , 2020, 104, 400-408.	1.1	3
92	Long-term outcome comparing histological grades of follicular lymphoma patients treated with immunochemotherapy as first-line therapy: A retrospective analysis from two institutions. <i>European Journal of Haematology</i> , 2020, 104, 198-206.	1.1	3
93	POLARGO: A Randomized Phase III Study Evaluating Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Who Had Received One or More Previous Therapies. <i>Blood</i> , 2019, 134, 5317-5317.	0.6	3
94	Phase 2 Randomized Trial Comparing Standard RCHOP Versus Brcap (bortezomib, rituximab,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 632 High-Risk Diffuse Large B-Cell Lymphoma (DLBCL). a Study from Spanish Group Geltamo. <i>Blood</i> , 2016, 128, 4201-4201.	0.6	3
95	A case of non-lethal pulmonary air embolism after leukapheresis catheter removal. <i>Journal of Clinical Apheresis</i> , 2005, 20, 93-94.	0.7	2
96	<scp>m7FLIPI</scp> and targeted sequencing in high-risk follicular lymphoma. <i>Hematological Oncology</i> , 2019, 37, 564-568.	0.8	2
97	Is Longer Progression-Free Survival a Goal Worth Pursuing in Follicular Lymphoma?. <i>Journal of Clinical Oncology</i> , 2019, 37, 758-758.	0.8	2
98	Further Examining the TROG 99.03 Trial in Early-Stage Follicular Lymphoma: Cure Rate and the Role of Positron Emission Tomography. <i>Journal of Clinical Oncology</i> , 2019, 37, 256-257.	0.8	2
99	The Prognostic Significance of Complex Karyotype in Philadelphia Chromosome-Negative (Ph <sup>-</sup> ) Acute Lymphoblastic Leukemia (ALL) in Adults Is Related with Risk Group.. <i>Blood</i> , 2007, 110, 3501-3501.	0.6	2
100	Prevalence, Predictive Factors Therapy and Outcome of Patients with Follicular Lymphoma Refractory to First Line Immunochemotherapy. <i>Blood</i> , 2015, 126, 1510-1510.	0.6	2
101	Incidence, Risk Factors and Prognosis of Transformation in Follicular Lymphoma: a Multicentre Retrospective Analysis of 1763 Patients from the Geltamo Spanish Lymphoma Cooperative Group. <i>Blood</i> , 2015, 126, 3944-3944.	0.6	2
102	Double-blind, randomized phase 3 study to compare efficacy and safety of the biosimilar CT-P10 to rituximab combined with CVP therapy in patients with previously untreated advanced-stage follicular lymphoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7532-7532.	0.8	2
103	The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study. <i>Cancers</i> , 2022, 14, 791.	1.7	2
104	Validation of the Burkitt Lymphoma International Prognostic Index in patients treated with two prospective chemoimmunotherapy trials in Spain. <i>Leukemia and Lymphoma</i> , 2022, 63, 1993-1996.	0.6	2
105	Participatory action research intervention for improving sleep in inpatients with cancer. <i>Journal of Clinical Nursing</i> , 2022, , .	1.4	2
106	Systemic thrombotic thrombocytopenic purpura (TTP) following unrelated cord blood transplantation. <i>Leukemia and Lymphoma</i> , 2006, 47, 1173-1175.	0.6	1
107	Mobilization of peripheral blood stem cells with plerixafor in poor mobilizer patients. <i>Medicina Clínica (English Edition)</i> , 2016, 147, 223.e1-223.e7.	0.1	1
108	Pronóstico similar de los linfomas transformados y los linfomas difusos de células B grandes de novo en pacientes tratados con inmunoterapia. <i>Medicina Clínica</i> , 2017, 148, 243-249.	0.3	1

#	ARTICLE	IF	CITATIONS
109	Venous thromboembolism in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with lenalidomide: a systematic review. <i>Leukemia and Lymphoma</i> , 2018, 59, 2602-2611.	0.6	1
110	A Phase 2b Study of Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S248-S249.	0.2	1
111	Overall survival in patients with relapsed/refractory high grade B-cell lymphomas treated with gemcitabine, oxaliplatin with or without rituximab. <i>Leukemia and Lymphoma</i> , 2019, 60, 3324-3326.	0.6	1
112	Impact of previous admission to an intensive care unit on stem cell transplantation outcome. <i>Medicina Clínica</i> , 2020, 155, 382-387.	0.3	1
113	The interval between frontline treatment and the second relapse (PFS2) predicts survival from the second relapse in follicular lymphoma patients. <i>European Journal of Haematology</i> , 2021, 106, 428-432.	1.1	1
114	The lymphocyte-to-monocyte ratio in follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-4.	0.6	1
115	Effect of Prior Therapy on the Efficacy and Safety of Oral Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the Sadal Study. <i>Blood</i> , 2019, 134, 5333-5333.	0.6	1
116	Efficacy of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with High-Risk Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the L-Mind Study. <i>Blood</i> , 2020, 136, 1-2.	0.6	1
117	Rituximab, Bendamustine, Mitoxantrone, Dexamethasone (R-BMD) in Patients with Follicular Lymphoma in Relapse or Refractory to First-Line Treatment with Immunochemotherapy. R-BMD Geltamo 08 Trial. <i>Blood</i> , 2012, 120, 1639-1639.	0.6	1
118	Lymphomas With MYC-Translocation Other Than Burkitt's Have An Aggressive Presentation and Poor Response To Immunochemotherapy: Study Of 34 Cases. <i>Blood</i> , 2013, 122, 5083-5083.	0.6	1
119	Incidence, Treatment and Prognosis of Patients with Relapsed Burkitt Lymphoma/Leukemia Treated with Specific Chemotherapy or Immunochemotherapy in Spain. <i>Blood</i> , 2015, 126, 2723-2723.	0.6	1
120	R-COMP Vs. R-CHOP As First-Line Treatment for De Novo Diffuse Large B-Cell Lymphoma in Patients Older Than 60 Years: Preliminary Results from a Prospective Randomized Phase 2 Study from the Spanish Group Geltamo. <i>Blood</i> , 2016, 128, 5387-5387.	0.6	1
121	Central Nervous System (CNS) Relapse in Adult Patients with Acute Lymphoblastic Leukemia (ALL): Frequency and Prognosis in 467 Patients without Cranial Irradiation for CNS Prophylaxis. <i>Blood</i> , 2005, 106, 1841-1841.	0.6	1
122	Comparison of Efficacy and Safety of Biosimilar CT-P10 to Rituximab in Patients with Previously Untreated Low Tumor Burden Follicular Lymphoma (LTBFL): A Randomized Phase III Study. <i>Blood</i> , 2018, 132, 1596-1596.	0.6	1
123	Rituximab and Specific Therapy for Patients with Burkitt's Leukemia and Lymphoma. Results of the BURKIMAB14 Trial from the Spanish Pethema and Geltamo Groups in 80 Patients. <i>Blood</i> , 2019, 134, 2584-2584.	0.6	1
124	Long-Term Efficacy and Safety (27 months) of the Biosimilar CT-P10 in Patients with Low Tumor Burden Follicular Lymphoma. <i>Blood</i> , 2020, 136, 27-28.	0.6	1
125	Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.2	1
126	Late isolated intraocular relapse of a systemic diffuse large B-cell lymphoma detected by flow cytometry. <i>Annals of Hematology</i> , 2017, 96, 523-524.	0.8	0



#	ARTICLE	IF	CITATIONS
127	Arterial Thromboembolism in Non-Hodgkin Lymphoma. Journal of the American College of Cardiology, 2018, 71, 258-259.	1.2	0
128	Segundas neoplasias en pacientes adultos receptores de un trasplante de progenitores hematopoyéticos. Medicina Clínica, 2018, 150, 421-427.	0.3	0
129	The case for lymphoma-specific survival. Expert Review of Hematology, 2018, 11, 263-264.	1.0	0
130	Predictive gene-expression score for follicular lymphoma. Lancet Oncology, The, 2018, 19, e279.	5.1	0
131	The persistent uncertainty of when to recommend allogeneic stem cell transplantation in follicular lymphoma. Cancer, 2018, 124, 3454-3455.	2.0	0
132	Outcome and Prognostic Factors in Patients with Hematological Malignancy That Are Admitted to the Intensive Care Unit.. Blood, 2004, 104, 5285-5285.	0.6	0
133	Applicability of Different Immunohistochemistry Algorithms to Assess Gene Expression Profile In Patients with Diffuse Large B-Cell Lymphoma. Blood, 2010, 116, 4134-4134.	0.6	0
134	Dose-Adjusted EPOCH Plus Rituximab in Untreated Patients with Poor Prognosis Large B-Cell, with Analysis of Germinal Center and Activated B-Cell Biomarkers. A Phase IV Study Conducted by the Spanish PETHEMA Group. Blood, 2011, 118, 593-593.	0.6	0
135	Differences In Clinical-Biological Features and Outcome Between Diffuse Large B-Cell Lymphomas Of HIV-Infected and Non-HIV-Infected Patients Treated With RCHOP In The CART Era. Blood, 2013, 122, 1815-1815.	0.6	0
136	Advanced Stage Hodgkin's Lymphoma Has More Aggressive Characteristics but Similar Outcome in HIV-Infected Than in HIV-Negative Patients in the Combination Antiretroviral Therapy Era. Blood, 2014, 124, 4435-4435.	0.6	0
137	Epstein-Barr Virus Viral Loads and Serum Free Light Chains Levels Are Diagnostic Markers of Lymphoma in HIV-Infected Patients. Blood, 2014, 124, 1697-1697.	0.6	0
138	Validation of the NCCN-IPI for Diffuse Large B-Cell Lymphoma (DLBCL) in a Nation-Wide Spanish Series of 1885 Patients. the Geltamo-IPI Project. Blood, 2015, 126, 3955-3955.	0.6	0
139	Prognostic Factors and Treatment Results in Elderly Patients with Aggressive B-Cell Lymphoma: A Geltamo Observational Study. Blood, 2015, 126, 1508-1508.	0.6	0
140	Phase 2 Randomized Trial Comparing 6 Cycles of Standard RCHOP Chemotherapy Vs 6 Cycles of Brcap (bortezomib, rituximab, cyclophosphamide, adriamidine and prednisone) As First Line Treatment in Young Patients with Poor Prognosis Diffuse Large B-Cell Lymphoma (DLBCL): Interim Analysis. Blood, 2015, 126, 1514-1514.	0.6	0
141	Gene Rearrangements and Other Molecular Features in Aggressive B-Cell Lymphomas of Patients with and without HIV-Infection. Blood, 2015, 126, 3874-3874.	0.6	0
142	Lenalidomide in Combination with R-ESHAP (LR-ESHAP) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Who Are Candidates for Autologous Stem-Cell Transplantation: A Phase 2 Study from the Spanish Group Geltamo. Blood, 2016, 128, 1850-1850.	0.6	0
143	Integrating Genomic Alterations in Diffuse Large B-Cell Lymphoma Identifies New Relevant Pathways and Potential Therapeutic Targets. Blood, 2016, 128, 152-152.	0.6	0
144	The effect of duvelisib, a dual inhibitor of PI3K- $\hat{1}$ , $\hat{3}$ , on components of the tumor microenvironment in previously untreated follicular lymphoma.. Journal of Clinical Oncology, 2018, 36, 7579-7579.	0.8	0

#	ARTICLE	IF	CITATIONS
145	Evaluation of the Effectiveness and Safety of Pixantrone for the Treatment of Multiply Relapsed or Refractory Aggressive Non Hodgkin B-Cell Lymphoma (aNHL) an Observational Multicentre Retrospective Study in a Real World Population. <i>Blood</i> , 2018, 132, 1716-1716.	0.6	0
146	Idelalisib for Relapsed/Refractory Follicular Lymphoma: Retrospective Study from Spanish Lymphoma Group Geltamo (GELT-IDE-2018-02). <i>Blood</i> , 2019, 134, 5249-5249.	0.6	0
147	Validation of New International Prognostic Scores, Including Baseline Peripheral Blood Variables, in Patients with Diffuse Large B-Cell Lymphoma and HIV Infection Treated with R-CHOP and Combined Antiretroviral Therapy. Retrospective Study from Spanish Lymphoma Group Geltamo. <i>Blood</i> , 2021, 138, 2497-2497.	0.6	0
148	IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice. <i>International Journal of Hematology</i> , 2022, , .	0.7	0